Showing 61-70 out of 74
Page 7 of 8« First«...45678»
HAE Patients Decision to Carry On-demand Treatment When Away from HomeBetschel S, van Kooten S, Heckmann M, Danese S, Goga L, Guilarte M
C1 Inhibitor Workshop 2023
Route of Administration Preferences of People with Hereditary Angioedema for On-demand Treatment: A US-based Qualitative StudyDesai V, Ledia Goga L, Czado S, Brown M, Myers K, Bukstein D, Audhya PK, Bouillet L
C1 Inhibitor Workshop 2023
Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 TrialBernstein JA, Riedl MA, Lumry WR, Audhya PK, Smith MD, Yea CM
AAAAI 2023
A Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy VolunteersSmith MD, Iverson M, Hansen E, Audhya PK, Yea CM
AAAAI 2023
Anxiety Associated With Parenteral On-demand Treatment For Hereditary Angioedema (HAE)Burnette A, Anderson J, Longhurst H, van Kooten S, Heckmann M, Danese S, Goga L
AAAAI 2023
Targeted Literature Review to Assess the Studies Supporting Short-term Prophylactic Treatment Options for the Preprocedural Prevention of Attacks in Patients With Hereditary AngioedemaRiedl MA, Bernstein JA, Lumry WR, Audhya PK, Smith MD, Yea CM
WSAAI 2023
Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice PatternsRiedl MA, Danese M, Danese S, Ulloa J, Maetzel A, Audhya PK
J Allergy Clin Immunol Pract
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On Demand Treatment for Hereditary AngiodemaDavie R, Edwards H, Evans D, Hodgson S, Stocks M, Smith A, Rushbrooke L, Pethen S, Roe M, Clark D, McEwan P, Hampton S
Journal of Medicinal Chemistry
Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900 following a single oral does in healthy male participantsMutch P, Bashir M, Jung B, Yi P, Iverson M
Xenobiotica
Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 TrialLonghurst HJ, Smith MD, Yea CM, Audhya PK
ASCIA 2022
